Intellia Therapeutics, Inc. (NTLA)

NGM – Real vaqt narxi. Valyuta: USD

12.09

+0.07 (0.58%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

12.20

+0.11 (0.91%)

Bozordan keyin: Aug 12, 2026, 4:49 PM EDT

07.08.2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on August 1, 2026, it awarded inducement grants to eight new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

07.08.2026

NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues

Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.

07.08.2026

Intellia Therapeutics Q2 Earnings Call Highlights

Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.

06.08.2026

Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript

06.08.2026

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.8 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.99 per share a year ago.

06.08.2026

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the second quarter ended June 30, 2026.

Videolar

No Data

There is no data to display

Press-relizlar

07.08.2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06.08.2026

Intellia Therapeutics, Inc. (NTLA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues

Intellia Therapeutics Q2 Earnings Call Highlights

Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Videolar

No Data

Press-relizlar

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues

Intellia Therapeutics Q2 Earnings Call Highlights

Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Videolar

No Data

Press-relizlar

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Search stocks

Intellia Therapeutics, Inc. (NTLA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues

Intellia Therapeutics Q2 Earnings Call Highlights

Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Videolar

No Data

Press-relizlar

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues

Intellia Therapeutics Q2 Earnings Call Highlights

Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Videolar

No Data

Press-relizlar

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates